The offered technology eradicates CDI via a microbiome-sparing intervention that kills Cdiff. The technology consists of an orally-delivered “platform” molecule that is complexed with a “cargo”, specifically, an antisense oligonucleotide designed to curtail C diff replication and kill the pathogen. The platform and cargo are both non-toxic to microbiota, human cells and in rodent models; therefore, the agent is precision-driven only for Cdiff. There is no bypass mechanism for the antisense oligonucleotide impact inside Cdiff, therefore, therefore, there is no possibility of resistance (the agent does not act as an antibiotic). Importantly, the “cargo”, i.e. antisense oligonucleotide, can be easily modified to target any infectious pathogen; thus, the entire technology is predicated on flexibility and precision.